Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 7Phase 1 6Phase 1/2 4

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Other hematologic neoplasm 2Lymphoid 2Tumor-Agnostic 1Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Melanoma 1Estrogen Receptor Positive Breast Cancer 1

Interventions

Trastuzumab 72Paclitaxel 63Cyclophosphamide 56pembrolizumab 52Fulvestrant 42Carboplatin 39Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 20Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × capivasertib × Breast × Clear all
NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Aminex Therapeutics, Inc.

Phase 1/2 Recruiting
92 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

NCT03742102 2026-04-24

BEGONIA

AstraZeneca

Phase 1/2 Active not recruiting
243 enrolled 13 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Stemline Therapeutics, Inc.

Phase 1/2 Recruiting
435 enrolled
Breast

Breast Neoplasms

NCT01992952 2025-11-26

FAKTION

Velindre NHS Trust

Phase 1/2 Active not recruiting
149 enrolled
Breast

Estrogen Receptor Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡